Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Imatinib ± Peginterferon alfa-2a in newly diagnosed chronic phase CML
2004-001622-24Phase 3Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jan 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib and interferon alfa in chronic myelogenous leukemia (CML) (3 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Overall survival at 5 years. Started Jan 2005; status: completed.
02
Drugs
imatinibinterferon alfa
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2004-001622-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001622-24.